Methylprednisolone, administered in high doses (30 mg kg ±1 ), reduces neurological damage and promotes functional recovery following central nervous system injury in animal studies, 27 and is an established therapy to improve neurological recovery after spinal cord injury in humans.
Methylprednisolone, administered in high doses (30 mg kg ±1 ), reduces neurological damage and promotes functional recovery following central nervous system injury in animal studies, 27 and is an established therapy to improve neurological recovery after spinal cord injury in humans. 10 At these doses, methylprednisolone inhibits lipid peroxidation of neuronal, glial and vascular membranes caused by oxygen free radicals, 3 4 12 13 a process implicated in the pathophysiology of secondary central nervous system (CNS) injury. 4 The neuroprotective effects are independent of its glucocorticoid receptor actions. The realization that the ef®cacy of methylprednisolone in reducing secondary injury was separate from its hormonal activity stimulated the development of a group of steroid analogues, the lazaroids (21-aminosteroids) , that speci®cally inhibited lipid peroxidation without glucocorticoid or mineralocorticoid activity, thereby avoiding the complications of corticosteroid therapy.
Lipid peroxidation and cerebral injury
During ischaemia and reperfusion injury of the CNS, mitochondrial dysfunction produces oxygen free radicals that cause lipid peroxidation of cell membranes resulting in membrane disintegration and increased microvascular permeability. Lipid peroxidation is catalysed by free iron derived from haemoglobin released from extravasated red blood cells. Disruption of neuronal, glial and vascular membranes inhibits Na + /K + ATPase and Ca 2+ ATPase. 68 This increases cellular in¯ux of calcium ions which activate phospholipase A 2 resulting in a release of arachidonic acid. The production of metabolites such as platelet-activating factor, prostaglandin E 2 andleukotriene B 4 enhances in¯am-mation. The oxygen free radicals and leukotriene B 4 activate neutrophils in the damaged tissues. Lipid peroxidation of cell membranes enhances further generation of oxygen free radicals and activation of phospholipase A 2 .
Ultimately, cell death with leakage of cytoplasmic components and arachidonic acid into the extracellular environment occurs. Lipid peroxidation of vascular endothelium also causes the increased permeability of the blood±brain barrier associated with trauma and ischaemic injury, and may produce prolonged cerebral vasospasm after subarachnoid haemorrhage. During ischaemia, superoxide anions (´O 2 ) are produced by enzyme±substrate reactions in the mitochondria, especially during reperfusion. Other sources of free radicals include the oxidation of monoamine neurotransmitters by monoamine oxidase and activated neutrophils that invade the CNS after trauma and hypoxaemia. Superoxide dismutase breaks the superoxide anion down to hydrogen peroxide (H 2 O 2 ), which is reduced to a highly reactive hydroxyl free radical (´OH). This reduction reaction is catalysed by ferrous ions. These free radicals (´OH,´O 2 ) are scavenged normally by membrane-bound endogenous antioxidants, especially vitamin E. In primary cerebral injury, the increased formation of these free radicals overwhelms the endogenous defence mechanisms.
Lipid peroxidation, initiated by a chain reaction involving oxygen free radicals, produces lipid peroxyl radical that attacks unsaturated fatty acids of membrane phospholipids, forming unstable, highly reactive lipid hydroperoxide radicals. Alpha-tocopherol, an important endogenous inhibitor, limits lipid peroxidation by scavenging lipid peroxyl radicals, thus preventing the lipid radical chain reaction from occurring.
The CNS is particularly susceptible to lipid peroxidation because its membrane lipids are rich in polyunsaturated fatty acids that possess reactive hydrogen. The brain has a relatively weak antioxidant capacity relative to other organs. In addition it is rich in intracellular iron which is released during injury, and the cerebrospinal¯uid (CSF) has less transferrin than plasma to bind the iron.
History of lazaroids
Early analogues of methylprednisolone that lacked glucocorticoid activity due to the substitution of the 11-b-hydroxy group (e.g. U-72099E; Fig. 1 ) were developed, but these inhibited lipid peroxidation weakly. The lazaroids are unique compounds possessing the membrane-stabilizing effects of the glucocorticoids without the receptordependent side effects. One of these compounds, tirilazad mesylate (U-74006F) has been selected for clinical development as a parenteral neuroprotective agent.
Mechanism of action
The lazaroids exert their anti-lipid peroxidation action through two mechanisms, free radical scavenging and membrane stabilization. Early animal studies of traumatic and ischaemic injury 31 35 70 suggest that the lazaroids inhibit membrane lipid peroxidation by scavenging peroxyl radicals, a mechanism similar to that of vitamin E.
14 In experimental head injury models, tirilazad decreased hydroxyl radical production in the brain of mice produced by concussive head injury, and in gerbils with bilateral carotid occlusion indicating that it may also scavenge hydroxyl radicals. 1 5 34 The lazaroids also have potent cell membrane-stabilizing effects. They have a high af®nity for the lipid bilayer and are incorporated into the lipid bilayer. 38 The positively charged piperazine nitrogen in tirilazad interacts with the negatively charged phosphate-containing head groups of the membrane lipids 29 (Fig. 2) . The localization of the bulky 21-amino moiety towards the surface compresses the membrane phospholipid head groups. This membrane-stabilizing action restricts the movement of lipid peroxyl radicals within the membrane so that their interaction with neighbouring fatty acids is reduced, thus inhibiting lipid peroxidation.
Pharmacodynamics
Although tirilazad is lipophilic, it penetrates the blood±-brain barrier poorly. It is highly concentrated in the vascular endothelial cell membrane, 67 and this indicates an endothelial site of action. Tirilazad prevents increases in blood±brain barrier permeability in acute trauma 32 and subarachnoid haemorrhage 87 in animal models. This is mediated by preservation of endothelial function via reduction of oxygen radical damage, and maintenance of production and function of endothelial nitric oxide. 18 In cerebral injury, a loss of endothelial function contributes to the loss of autoregulation, microvascular hypoperfusion and vasospasm. However, direct neuronal protection by tirilazad cannot be ruled out because enhanced penetration into brain parenchyma, caused by increased blood±brain barrier permeability, 34 has been observed after trauma.
Pharmacokinetics
The pharmacokinetics of tirilazad has been studied after single and multiple doses. Tirilazad is extensively distributed in body tissues. It is 99% protein bound with a volume of distribution of~3.33 litres kg ±1 . 20 With multiple doses at 2 mg kg ±1 day ±1 and above, its terminal half-life is 35 h, so that a steady state is achieved after 5 days of dosing. The hepatic clearance of tirilazad is dependent on hepatic blood¯ow suggesting that it has a medium to high hepatic extraction ratio. 21 Tirilazad is metabolized in the liver to several inactive oxidative products and a reduced metabolite, U-89678, which is active. 80 The clearance of tirilazad and its active metabolite (U-89678) is slightly greater in women, 42 due to gender differences in either hepatic blood¯ow, or metabolism of the steroid moiety of the molecule. 52 81 The elimination of tirilazad is increased by enzyme-inducing anticonvulsants such as phenytoin. 19 Only 12% of the dose may be recovered in the urine and most of it is in the faeces. 76 
Side effects
Extensive animal and human studies of single and multiple doses of tirilazad (up to 6 mg kg ±1 day ±1 for 5 days) demonstrated minimal changes in heart rate, blood pressure or cardiac rhythm. It does not signi®cantly affect plasma glucose, cortisol or adrenocorticotrophin concentrations and temperature regulation. 20 21 A transient rise in serum alanine transaminase concentrations in human subjects receiving 6 mg kg ±1 day ±1 for 5 days has been reported. 21 The most common side effect is pain at the injection site caused by the vehicle (0.02 M citric acid monohydrate, 0.0032 M sodium citrate dihydrate, 0.077 M NaCl, pH 3). 21 Central nervous system trauma Free radical production and lipid peroxidation are early biochemical events in the pathogenesis of traumatic brain injury. In CNS trauma, tissue haemorrhage initiates free radical formation, and iron compounds released from blood cells catalyse the formation of hydroxyl radicals and stimulate membrane lipid peroxidation. Free radicals are known to increase blood±brain barrier permeability and lazaroids may protect the blood±brain barrier by reducing hydroxyl radicals or protect the microvascular endothelium from lipid peroxidation.
Preventing and reducing secondary brain injury have been the main areas of CNS trauma research. In head injury, the therapeutic ef®cacy of the lazaroids has been focussed on their role on membrane damage resulting from free radical reactions and the disruption in cellular ionic homeostasis, with less attention to other pathophysiological mechanisms such as release of excitotoxic amino acids.
Experimental data
Head injury Studies on functional outcome in animal models of head injury demonstrated bene®cial effects of tirilazad. Mice receiving doses of tirilazad ranging from 0.003 to 30 mg kg ±1 at 5 min after a standard head injury were signi®cantly better neurologically after 1 h compared with controls. Mice treated with tirilazad 1 mg kg ±1 at 5 min and 1 h post-injury had a survival of 78.6% at 1 week compared with 27.3% in the control group. 36 Male Sprague±Dawley rats subjected to brain injury produced by¯uid percussion over the left parietal cortex had no mortality at 48 h post-injury when tirilazad 3 mg kg ±1 was administered at 15 min and 3 h postinjury, compared with a mortality of 28% in control groups. 57 However, in another study, rats that were hypoxic for 45 min after a standard head injury received doses of tirilazad varying from 1 to 30 mg kg ±1 at 3 min and 3 h after injury. Only the group receiving tirilazad at 10 mg kg ±1 showed signi®cantly improved motor scores measured at 24 h after injury. 69 Further studies demonstrated the bene®cial effects of tirilazad on cerebral metabolic function, blood±brain barrier permeability and cerebral oedema in animals. Tirilazad 1 mg kg ±1 administered to female mongrel cats 30 min after a severe unilateral cerebral contusion, with a further dose of 0.5 mg kg ±1 2.5 h after injury, improved the metabolic state in the neighbouring non-oedematous white matter (indicated by the glucose, lactate and glycogen concentrations). 16 Oedema and the amount of metabolites in contused tissue were similar in vehicle-treated and drug-treated groups.
In a head injury model in rats, tirilazad diminished the post-traumatic increase in blood±brain barrier permeability. Tirilazad 10 mg kg ±1 administered 5 min post-injury reduced parenchymal extravasation of protein-bound Evans blue at 30 min by 52%. 32 Using autoradiographic techniques, tirilazad 10 mg kg ±1 has been shown to reduce microvascular changes in permeability when administered 5 min after head injury in rats. 56 Another 21-aminosteroid, U-74389F, administered over a range of doses pre-and postinjury, reduced brain swelling in Sprague±Dawley rats exposed to a cryogenic brain injury. 72 
Spinal cord injury
Animal studies 17 40 41 demonstrated that tirilazad improved functional recovery and blood¯ow in the white matter of the spinal cord during injury. Female mongrel cats receiving tirilazad 0.16±160 mg kg ±1 48 h ±1 followed by an infusion for 42 h after a spinal cord injury had improved functional recovery 3 weeks post-injury compared with the control group.
2 Tirilazad (single dose of 10 mg kg ±1 ) prevented the fall in blood¯ow in spinal cord white matter after a spinal cord injury in cats. Normal blood¯ow in the white matter of the spinal cord was reported 4 h post-injury, compared with a 63% decreased¯ow in the control groups. 26 However, tirilazad 3 mg kg ±1 administered 30 min before spinal cord injury in rats, and 1.5 mg kg ±1 every hour after injury failed to attenuate the rise in plasma lactate and glutamate concentrations (markers of ischaemia). Most signi®cantly, the lowering of lactate and arginine concentrations early after trauma observed with methylprednisolone pre-treatment was absent after pre-treatment with tirilazad. 17 
Clinical data
In a multi-centre trial evaluating tirilazad in patients with head injury, 54 1120 patients received at least one dose of either tirilazad or placebo. Eighty-®ve percent of the patients had severe and 15% moderate head injury (Glasgow Coma Score 4±8). After 6 months, there was no difference in functional recovery or mortality. Subgroup analysis suggested an improvement in mortality in males with severe head injury and accompanying traumatic subarachnoid haemorrhage who received tirilazad. However, there were differences between the two groups with respect to prognostic variables such as pre-treatment hypotension, pre-treatment hypoxaemia and epidural haematoma. 54 In a randomized, double-blind multi-centre trial 11 investigating the ef®cacy of tirilazad in spinal cord injury, 499 patients with spinal cord injury diagnosed within 8 h of injury were randomized into three groups. All patients received an initial bolus of methylprednisolone 30 mg kg ±1 . The ®rst group received standard therapy of a methylpred-nisolone infusion of 5.4 mg kg ±1 h ±1 for 24 h. The second group received a similar infusion for 48 h. The tirilazad group received tirilazad (2.5 mg kg ±1 boluses) every 6 h for 48 h. Patients who received tirilazad had equivalent recovery rates to those patients receiving methylprednisolone for 24 h with respect to motor function changes and functional independence at 6 weeks and 6 months. However, those patients who received therapy within 3±8 h after injury had a signi®cantly better outcome at 6 months (P=0.01) with a regimen of methylprednisolone for 48 h, compared with a regimen of methylprednisolone for 24 h or tirilazad for 48 h. Although the group receiving tirilazad for 48 h had fewer complications, this was not clinically or statistically signi®cant. It was postulated that the reduced ef®cacy of tirilazad compared with methylprednisolone might be due to a suboptimal dosage. Further analysis showed that the patients randomized to receive tirilazad had signi®cantly worse motor scores prior to treatment compared with the other groups. 11 In conclusion, the study did not justify the use of tirilazad clinically in spinal injuries, and further studies with higher doses and longer regimes are required.
Central nervous system ischaemia
There is considerable evidence of lipid peroxidation in cerebral ischaemia. During and after an ischaemic insult, cellular calcium in¯ux in¯uences the extent of neuronal injury. In addition, post-ischaemic production of lactate in the damaged tissues causes mitochondrial dysfunction resulting in the generation of toxic free radicals. Animal studies have indicated that tirilazad may attenuate cell damage with transient or permanent focal ischaemia associated with thromboembolism, and transient global ischaemia in cardiopulmonary arrest.
Experimental data Focal transient ischaemia
In a model of temporary hemispheric cerebral ischaemia in Mongolian gerbils, tirilazad 10 mg kg ±1 , when administered before and after a 3-h unilateral carotid artery occlusion, signi®cantly improved the 24 and 48 h survival, and preserved neurones in the hippocampus and lateral cortex. 30 The neuroprotective mechanisms of tirilazad attenuated post-ischaemic depletion of vitamin E, 70 improved postischaemic recovery in extracellular calcium levels, 31 preserved levels of the antioxidant ascorbic acid, 68 and diminished hydroxyl radical production during reperfusion. 5 Tirilazad also decreased the in®ltration of neutrophils into the reperfused hemisphere 61 associated with reduced brain concentrations of the leukotrienes C 4 and B 4 postischaemia. 6 In cats, tirilazad, administered as a series of boluses after middle cerebral artery occlusion for 1 h, reduced infarct size 71 73 but had no effect when the arterial occlusion was prolonged to 90 min. 22 77 In focal ischaemia, tirilazad 10 mg kg ±1 administered to Wistar rats 2 h before middle cerebral artery occlusion (for a 2-h period) reduced post-ischaemia infarct volume at 24 h by 67% compared with controls. 83 In a similar study with male Sprague±Dawley rats, tirilazad administered before and after a 90-min occlusion of the middle cerebral artery reduced infarct size at 24 h by 48%, compared with controls. 71 In Cynomolgous monkeys subjected to 3 h middle cerebral artery occlusion, the administration of tirilazad 3 mg kg ±1 10 min before reperfusion attenuated post-ischaemia brain oedema. 9 Permanent focal ischaemia As lazaroids act primarily by preventing damage caused by free radicals generated during cerebral reperfusion after a period of ischaemia, it is suggested that lazaroids are most effective in transient ischaemia and less effective in permanent ischaemia. However, there are good experimental data to support their role in therapy for permanent focal ischaemia. 62 A number of studies investigating the effects of single or multiple doses of tirilazad 1±3 mg kg ±1 administered after permanent unilateral middle cerebral artery occlusion in Sprague±Dawley rats have reported a reduction in infarct size and oedema formation. 8 53 85 A reduction in cerebral oedema, Na + accumulation and K + loss mainly limited to areas of the cortex adjacent to the infarct site has been demonstrated. 85 In a similar rat model of permanent focal ischaemia, tirilazad signi®cantly reduced the amount of lipid peroxidation products and free arachidonic acid in the infarcted hemisphere. The extent of ischaemic damage is signi®cantly correlated with the concentration of these products. 78 However, two studies investigating tirilazad 10 mg kg ±1 failed to show a protective effect in models of permanent focal ischaemia in the spontaneously hypertensive rats 84 and hyperglycaemic cats. 59 Tirilazad has been shown to be ef®cacious in two rabbit models of thromboembolic stroke. Pre-and post-treatment with tirilazad of rabbits subjected to an internal carotid arterial injection of a 3.5-cm embolus signi®cantly reduced infarct size in the affected hemisphere. 82 In the second study, microspheres were injected into the internal carotid artery until a functional de®cit was produced. In this study, pre-treatment but not post-treatment with tirilazad 3 mg kg ±1 doubled the number of microspheres needed to produce a 50% functional de®cit. 15 
Global cerebral ischaemia
The ef®cacy of tirilazad in cardiac arrest and resuscitation has been examined in animal models of global cerebral ischaemia and reperfusion. In a rat model (employing transient bilateral carotid occlusion with hypotension for 10 min), tirilazad, in doses ranging from 0.3 to 10 mg kg ±1 given before and after the ischaemic injury, abolished postischaemic increases in nitric oxide synthase and cyclic guanosine monophosphate concentrations in brain homogenates 18 and reduced cortical neuronal loss. 51 Another study showed that when tirilazad was given before or after ischaemia, there was a faster recovery of high-energy phosphates during early reperfusion. 37 In this model, however, selectively vulnerable neurones in the hippocampus and striatum were not protected by tirilazad. 8 39 51 However, the production of toxic hydroxyl radicals in the rat hippocampus during ischaemia and reperfusion is attenuated by lazaroids. 86 When the duration of global ischaemia was increased to 30 min, the protective effect of tirilazad was lost. 45 64 Other animal models of global ischaemia have also shown a generally positive outcome with tirilazad. In a model of incomplete cerebral ischaemia in anaesthetized dogs, 55 cerebral perfusion pressure was reduced to 12 mm Hg for 30 min with an intraventricular¯uid infusion. Tirilazad 1 mg kg ±1 , administered pre-and post-ischaemia, augmented recovery of inorganic phosphate and somatosensory-evoked potentials with resolution of intracellular acidosis during reperfusion and decreased cerebral oedema. 55 Tirilazad 0.25±2.5 mg kg ±1 administered only in the reperfusion stage signi®cantly improved recovery in cerebral oxygenconsumption, cerebral blood¯ow, ATP and the resolution of intracellular acidosis in this dog model. 47 When complete cerebral ischaemia was produced for 12 min in anaesthetized dogs by raising ICP above systemic arterial pressure with ventricular¯uid infusion, functional recovery at 48 h markedly improved with tirilazad 1.5 mg kg ±1 given before and after ischaemia. 63 However, tirilazad had no effect on the recovery of intracellular pH, oxygen consumption, somatosensory-evoked potentials and cerebral blood¯ow during a 3-h reperfusion phase. 23 
Clinical data
Clinical studies looking at the cerebroprotective ef®cacy of tirilazad in cerebral ischaemia have been disappointing. A large prospective double-blind, randomized trial in which 660 patients received either vehicle (control) or tirilazad 6 mg kg ±1 day ±1 for 3 days (with the ®rst dose given within 6 h of onset of acute stroke) evaluated the outcome at 3 months after stroke. 65 Tirilazad had no positive effect on the Glasgow Outcome Scale and the Barthel index of activities of daily living. The odds ratio of a favourable outcome in favour of tirilazad was 0.87 (95% con®dence interval, 0.6±1.25) for both the Glasgow Outcome Scale and the Barthel Index. This lack of bene®t might be due to inadequate dosage. A second clinical study 66 using higher doses in both men (12.5 mg kg ±1 on day 1 and then 10 mg kg ±1 day ±1 for 2 days) and women (15 mg kg ±1 on day 1 then 12.5 mg kg ±1 day ±1 for 2 days) was conducted. One hundred and twenty-six patients were enrolled and matched for baseline characteristics in each treatment group. Tirilazad was associated with an absolute reduction in mortality of 14% in both sexes. However, the numbers in this study were small and the differences were not statistically signi®cant. 66 No clinical studies evaluating the role of tirilazad in cerebroprotection during cardiopulmonary resuscitation have been conducted as yet.
It is important to emphasize that the mediators of secondary damage during ischaemia and reperfusion include release of excitotoxic amino acids, free radicals and microcirculatory disturbances. Free radical damage of cell membranes is only one pathophysiological mechanism of many during reperfusion. A combination of several therapeutic modalities such as arterial pressure stabilization, glutamate antagonists and correction of tissue acidosis may signi®cantly improve outcome.
Subarachnoid haemorrhage
Following subarachnoid haemorrhages, secondary cerebral ischaemia occurs as a result of microvascular hypoperfusion associated with a decrease in blood±brain barrier permeability, vasogenic oedema, increased intracranial pressure and delayed vasospasm. Lipid peroxidation in the arterial walls after SAH plays an important role in genesis of vasospasm.
Experimental data Effect on cerebral microvascular hypoperfusion
In a model of subarachnoid haemorrhage produced by injecting autologous blood into the cisternae magna of anaesthetized cats, tirilazad 0.1 mg kg ±1 and 1 mg kg ±1 administered 30 min after the insult attenuated signi®cantly the fall in blood¯ow in the caudate nucleus and diminished the increase in intracranial pressure. It also attenuated the concomitant fall in mean arterial pressure and cerebral perfusion pressure. 33 Effect on blood±brain barrier permeability Endothelial cell cultures undergo marked increase in permeability when exposed to haemolysed red cells. This was signi®cantly attenuated by pre-treatment with tirilazad, 48 indicating that free radical generation causing lipid peroxidation was a critical mechanism responsible for the increased permeability. Two studies 72 87 investigating the effect of pre-and post-treatment with tirilazad on blood±-brain barrier permeability after the injection of autologous blood into the subarachnoid spaces of rats showed that tirilazad signi®cantly attenuated the increase in permeability to albumin compared with control. Tirilazad has been shown to attenuate increased blood±brain barrier permeability associated with subarachnoid injection of arachidonic acid and FeCl 2 .
87
Effects on delayed cerebral vasospasm Tirilazad is potentially bene®cial in the management of delayed onset vasospasm as its action is primarily at the vascular endothelium. Lipid peroxidation plays a substantial role in cerebral vasospasm, 7 which normally occurs several days after the initial subarachnoid bleed. Consequently, therapy can be started before its onset.
In a canine model of subarachnoid haemorrhage, tirilazad 0.5 mg kg ±1 administered every 8 h for 6 days, either as an infusion or as boluses signi®cantly attenuated intraluminal narrowing of the basilar artery compared with control. 57 Three studies 43 44 75 using the Cynomolgous monkey model of subarachnoid haemorrhage have shown that tirilazad 0.3±3 mg kg ±1 administered every 8 h for 6 days posthaemorrhage, signi®cantly reduced middle cerebral artery vasospasm. However, tirilazad did not signi®cantly attenuate internal carotid artery and the anterior cerebral artery vasospasm. In a rabbit model, tirilazad 1 mg kg ±1 , given 12 h before the onset of experimental subarachnoid haemorrhage completely eliminated basilar artery vasospasm (seen in the placebo group), as assessed by morphometric analysis at 48 h post-injury. 79 In the same model, tirilazad administered 30 min after the onset of subarachnoid haemorrhage abolished basilar artery vasospasm as assessed by digital subtraction angiogram at 72 h. 88 Vasospasm is the main treatable cause of death and disability following subarachnoid haemorrhage. Tirilazad is a potent scavenger of oxygen free radicals and an inhibitor of lipid peroxidation, which may play a central role in the development of vasospasm. However, more research is required before free radicals and reactions induced by them can be said to be the main cause of vasospasm.
Clinical data
Initial phase II trials with tirilazad in patients with subarachnoid haemorrhage were ®rst carried out in 1995. Tirilazad was administered in doses of 0.6, 2 and 6 mg kg ±1 day ±1 i.v. for 10 days after SAH, in conjunction with nimodipine. No serious side effects were demonstrated at any of the three doses and there was a trend towards improvement in patient outcome in the 2 mg kg ±1 day ±1 group compared with the vehicle-controlled group at 3 months. 24 More recently, there have been two large randomized, double-blind, controlled trials of tirilazad in patients with aneurysmal subarachnoid haemorrhage. The ®rst involved neurosurgical centres in Europe, Australia and New Zealand, and enrolled 1023 patients. The patients were assigned randomly to receive either 0.6, 2 or 6 mg kg ±1 day ±1 of tirilazad or placebo. The patients also received nimodipine. Patients in the 6 mg kg ±1 day ±1 group had a greater frequency of good recovery on the Glasgow Coma Scale at 3 months (P=0.01) and a reduced mortality (P=0.01). There was also a reduction in symptomatic vasospasm in this group, but the difference was not statistically signi®cant. The groups receiving 0.6 and 2 mg kg ±1 day ±1 showed no improvement. The bene®ts were predominantly in men. 46 The second trial involved 902 patients enrolled from 54 North American neurosurgical centres. Patients were allocated randomly to three treatment groups, receiving either vehicle (control), 2 or 6 mg kg ±1 day ±1 tirilazad beginning within 48 h of a SAH and continued for 10 days. At 3 months, there was no signi®cant difference in Glasgow Coma Score, mortality or employment status between the groups. There was also no signi®cant difference in the incidence of vasospasm between the groups. When the mortality data were strati®ed according to gender and neurological grade on admission, men with grades IV and V in the 6 mg kg ±1 day ±1 group had a mortality of 5% compared with 33% in the control group, but this was not statistically signi®cant (P=0.03). 25 The difference between the ®ndings of the trials could be explained by differences in admission characteristics or management protocols, including the use of anticonvulsant medications.
A further study looked at 31 women with SAH allocated randomly to receive either vehicle or 15 mg kg ±1 day ±1 tirilazad for 10 days, and looked at more sensitive neuropsychological and psychosocial outcomes. 60 There was no difference in 3-month Glasgow Coma Scale or mortality in the two groups, although the tirilazad group showed less impairment of concentration, sustained attention and psychomotor speed (P<0.02), and debilitating fatigue (P<0.01). However, this study group is too small to make any conclusions and the results would have to be con®rmed with larger patient groups.
A prospective double-blind, vehicle-controlled study 49 of high-dose tirilazad in 819 women with aneurysmal SAH randomized to receive 15 mg kg ±1 tirilazad or placebo was conducted at 56 neurosurgical centres in Europe, Australia, New Zealand and South Africa, and concluded that highdose tirilazad signi®cantly reduced the incidence of symptomatic vasospasm from 33.3% in the placebo group to 24.8% in patients treated with tirilazad. However, there was no difference in the 3-month mortality rate. The more frequent use of other potentially effective rescue therapy (hypervolaemia, haemodilution and induced hypertension) in the placebo group (33.3%) compared with the tirilazadtreated patients (24.8%) may have been responsible for these contrasting observations between the two groups. In North America, a double-blind randomized study in women involving 832 patients 50 found that high-dose tirilazad 15 mg kg ±1 day ±1 signi®cantly reduced the mortality from 43.4% to 24.6% among patients who were neurological grade IV or V on admission, con®rming the bene®cial effect observed in male patients in previous studies. 25 46 These latest ®ndings may in¯uence future management of highgrade cerebral aneurysms.
Discussion
It is well established that lipid peroxidation by free radicals is one of a number of biological mechanisms responsible for the secondary injury after traumatic or ischaemic injury to the CNS. The lazaroids are potent antioxidants, 100 times more potent than the corticosteroids, and therefore may be ef®cacious in the clinical management of acute CNS injury.
Experimental evidence in animal models of head injury, spinal cord injury, stroke and subarachnoid haemorrhage indicates that tirilazad obtunds secondary injury phenomena, promotes neurological recovery and improves outcome in these conditions. However, the evidence of the ef®cacy of tirilazad from phase III clinical trials is far from conclusive.
In the management of head trauma only one large clinical trial 54 has been carried out and showed no improvement in outcome. In spinal cord injury a 48-h infusion of tirilazad following an initial bolus of methylprednisolone was as effective as the established 24 h therapy with methylprednisolone. 11 However, tirilazad did not produce any additional bene®t over standard steroid therapy either in terms of improved neurological outcome or in a lower rate of serious long-term complications. In addition, patients treated for 48 h with methylprednisolone or tirilazad commenced 3±8 h post-injury had a better outcome with methylprednisolone compared with tirilazad. The only large phase III trial in stroke patients showed no improvement in outcome with tirilazad. 65 In subarachnoid haemorrhage, a large phase III trial showed an improvement in outcome with 6 mg kg ±1 day ±1 tirilazad administered for 10 days. 46 The effect was most marked in men in whom mortality was reduced from 20 to 6%. However, a second American study 25 failed to show any signi®cant bene®t with tirilazad, although there was a trend towards a better outcome in men with grade IV±V subarachnoid haemorrhage. However, two recent studies utilizing a high-dose (15 mg kg ±1 day ±1 ) regimen of tirilazad concluded that there was a signi®cant reduction in both the incidence of vasospasm and the mortality rate among women with aneurysmal subarachnoid haemorrhage.
Two possible conclusions can be drawn from the disparity between the bene®cial effects of tirilazad in preclinical animal studies compared with clinical trials. Firstly it may well be that tirilazad is ineffective as a cerebroprotectant after CNS injury in humans. It may be wrong to extrapolate the results of pre-clinical trials to humans because of controversy regarding the applicability of the animal model to human injury, the reproducibility of the model, and different responses of animals and humans to different drugs. The lazaroids do have limitations. Lipid peroxidation is only one of a number of biological mechanisms involved in the secondary injury, and other destructive secondary processes initiated by the primary insult such as the release of excitatory amino acid neurotransmitters and the loss of intracellular calcium homeostasis occur. The prevention of lipid peroxidation alone therefore may be ineffective in reducing the secondary injury. The poor penetration of the blood±brain barrier of the lazaroids and its localization in the vascular membrane may signi®cantly limit their ef®cacy. Their ability to prevent lipid peroxidation may be dependent upon administration within minutes of the primary insult, something rarely possible in the clinical situation. It is notable that in the experimental studies the ®rst dose of tirilazad was often administered within minutes of the primary insult, and in some studies the ®rst dose was given pre-injury. However, in the clinical studies looking at spinal cord injury 11 and stroke, 65 approximately half the patients received their ®rst dose of tirilazad more than 3 h postinjury, and this could contribute to the apparent lack of clinical ef®cacy.
However, the lack of ef®cacy of tirilazad in a number of clinical studies may have resulted from weaknesses within those studies. In the phase III study 54 looking at the effect of tirilazad compared with placebo in 1120 patients with head injuries, it was noted that there was a marked imbalance between the groups concerning the basic prognostic variables such as hypoxaemia and hypotension. It was also noted that there was a trend towards improved outcome in the small subgroup of patients with severe head injury associated with traumatic subarachnoid haemorrhage. It may be that a further study, using an alternate method of randomization and targeting populations with a higher risk of morbidity and mortality, would show an improved outcome with tirilazad.
It has also been suggested that the range of doses of tirilazad used in all these clinical studies (2±10 mg kg ±1 day ±1 ) may be suboptimal, and the ®ndings of the two important studies 49 50 of high-dose tirilazad in women with aneurysmal subarachnoid haemorrhage support this hypothesis. It may also explain the frequent ®nding that the bene®cial effects of tirilazad are limited to men, in whom metabolism of the steroid moiety of tirilazad is less ef®cient compared with women. In the large phase III clinical study looking at tirilazad (6 mg kg ±1 day ±1 for 3 days) in stroke patients there was no improvement in outcome. However, a second smaller study looking at larger doses (10±15 mg kg ±1 day ±1 for 3 days) did show a reduction in mortality of 14%, although the study group was too small to make the difference signi®cant. In the two large studies looking at the ef®cacy of tirilazad in the treatment of subarachnoid haemorrhage, one European, Australian and New Zealand study 46 has shown a marked improvement in outcome for men, whereas a second North American study 25 showed no difference in outcome. In the North American trial more than 80% of patients were on anticonvulsants, compared with 50% of patients in the ®rst trial. The increased elimination of tirilazad caused by enzyme-inducing anticonvulsants could have resulted in lower blood concentrations of the study drug in North American patients. Higher doses of the drug might have obviated the gender difference in the European study and improved the results in the North American study. Recent multicentre studies of high-dose (15 mg kg ±1 day ±1 ) tirilazad in women have indeed shown a signi®cant reduction in the incidence of vasospasm associated with aneurysmal subarachnoid haemorrhage and the mortality in patients who were neurological grade IV or V on admission. These ®ndings may well in¯uence future treatment of high-grade cerebral aneurysms.
At the present time, the clinical evidence available is not strong enough to justify the routine use of tirilazad in the management of CNS trauma, ischaemia or subarachnoid haemorrhage. However, further studies using larger doses of tirilazad may show signi®cant ef®cacy. 49 50 There is also increasing interest in using tirilazad in combination with thrombolytic agents in the management of ischaemic strokes. 74 Finally, there are now early animal studies investigating the pyrrolopyrimidines, 28 a group of antioxidants that have improved penetration of the blood±brain barrier and gain direct access to neural tissue.
